Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1) antibody

Antigen: Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1)

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Catalog no.: ABIN125884

Additional Information

Alternative name: Lig-1 rabbit antibody (LRIG1)

Immunogen: KLH-conjugated synthetic peptide, the peptide corresponds to part of thecytoplasmic tail (C-terminal part) of the protein

Format: Lyophilized

Description: LRIG1 protein Q96JA1 is coded by a gene on a chromosome band 3p14.3, thisregion is known to be deleted in various human cancers. LRIG1 is considered tobe a a tumour suppressor gene in humans. LRIG1 is an integral cell-surfacemembrane protein that is expressed by specific cells in various human tissuesand that its 143-kDa form might be cleaved into 111-kDa and 32-kDa fragments.The LRIG1 protein may inhibit the growth of tumors of glial cells and thedown-regulation of the LRIG1 gene may be involved in the development andprogression of the tumor.

Specificity: Predicted reactivity: human.

Application Details

Application Notes: Recommended Dilution 1 µg/ml (WB), use at an assay dependent dilution (IHC) MW. Additional Information: Recommended Dilution 1 µg/ml (WB), use at an assay dependent dilution (IHC).

Buffer: Affinity purified IgG in PBS pH 7.4, BSA 1mg/ml

Storage: store lyophilized/reconstituted at -20°C, once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please, remember to spin tubes briefly prior toopening them to avoid any losses that might occur from lyophilized materialadhering to the cap or sides of the tubes.

Restrictions: For Research Use only

Images

Western Blot has been done using: The COS-7 cells transfected with expression vectors encoding LRIG1 (line 1) or LRIG2 (Line 2) and ZR-75, a breast carcinoma cell line (Line 3). Loading: 0.5 microgram of COS-7 lysates and 10 microgram of ZR-75 lysate.

Publications

Publications: Ledda, Bieraugel, Fard et al.: "Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 28, Issue 1, pp. 39-49, 2008 (PubMed).

Stutz, Shattuck, Laederich et al.: "LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII." in: Oncogene, Vol. 27, Issue 43, pp. 5741-52, 2008 (PubMed).

Miller, Shattuck, Ingalla et al.: "Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer." in: Cancer research, Vol. 68, Issue 20, pp. 8286-94, 2008 (PubMed).

Thomasson, Wang, Hammarsten et al.: "LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer." in: International journal of cancer. Journal international du cancer, 2010 (PubMed).